70 related articles for article (PubMed ID: 17706119)
1. [Expression of macrophage migration inhibitory factor, p53 and CD34 in ovarian carcinoma].
He CZ; Xia XA; Wu YY; Pu H; Lü B; Mao YR; Zhang ZY; Gao WH
Zhonghua Bing Li Xue Za Zhi; 2007 Apr; 36(4):261-2. PubMed ID: 17706119
[No Abstract] [Full Text] [Related]
2. [Detection of CDX-2, CK7 and CK20 in primary and metastatic ovarian carcinoma].
Yuan ZF; Shi HR; Sun HM; Li WC
Zhonghua Bing Li Xue Za Zhi; 2007 Aug; 36(8):555-6. PubMed ID: 17980105
[No Abstract] [Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
5. Expression of leukaemia inhibitory factor in epithelial ovarian carcinoma: correlation with clinical characteristics.
Ye F; Hu Y; Lu W; Zhou C; Xie X
Histopathology; 2008 Aug; 53(2):224-8. PubMed ID: 18540977
[No Abstract] [Full Text] [Related]
6. [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
Shi HR; Zhang RT
Ai Zheng; 2009 Aug; 28(8):882-5. PubMed ID: 19664338
[TBL] [Abstract][Full Text] [Related]
7. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
[TBL] [Abstract][Full Text] [Related]
8. [Relationship of expression of C-erbB2, C-erbB3, and C-erbB4 with ovarian carcinoma].
Li L; Zhong YP; Zhang W; Zhang JQ; Yao ZQ
Ai Zheng; 2004 May; 23(5):568-72. PubMed ID: 15142456
[TBL] [Abstract][Full Text] [Related]
9. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas.
Mayr D; Pannekamp U; Baretton GB; Gropp M; Meier W; Flens MJ; Scheper R; Diebold J
Pathol Res Pract; 2000; 196(7):469-75. PubMed ID: 10926324
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
12. [The role of cytokeratin 7 in the differential diagnosis of primary ovarian carcinoma and metastatic ovarian carcinoma originated from the gastrointestinal tract].
Yang W; Zhang T; Shen M
Zhonghua Bing Li Xue Za Zhi; 1998 Jun; 27(3):206-8. PubMed ID: 11244983
[TBL] [Abstract][Full Text] [Related]
13. [Expression of EVEC in ovarian carcinoma and its biological significance].
Wang Q; Li XG; Zhang Y; Cao LQ; Deng ZH; Chen Y
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):676-80. PubMed ID: 21122382
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
16. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
[TBL] [Abstract][Full Text] [Related]
17. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
18. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.
Köbel M; Reuss A; du Bois A; Kommoss S; Kommoss F; Gao D; Kalloger SE; Huntsman DG; Gilks CB
J Pathol; 2010 Oct; 222(2):191-8. PubMed ID: 20629008
[TBL] [Abstract][Full Text] [Related]
19. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
Zhang MZ; Qiao YH; Suo ZH
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
